(Reuters) - The health of Valeant Pharmaceuticals International Inc's VRX.TO Michael Pearson is improving, the company said on Thursday, but CNBC reported that there was debate within the board over whether he was ready to return to work.
Pearson, who joined Valeant VRX.N as chief executive in 2010, was hospitalized with severe pneumonia in late December.
The company named former Chief Financial Officer Howard Schiller as interim CEO in January.
CNBC, citing a source, said Pearson was ready to return but the board was debating whether he should. (bit.ly/20X0uU8)
Reporting by Natalie Grover in Bengaluru; Editing by Ted Kerr
Our Standards: The Thomson Reuters Trust Principles.